Rosuvastatin extended release - Lyndra
Alternative Names: LYN-047Latest Information Update: 28 May 2026
At a glance
- Originator Lyndra
- Class Antihyperlipidaemics; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dyslipidaemias
Most Recent Events
- 28 May 2026 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in Australia (PO, Capsule)
- 30 May 2024 Rosuvastatin extended release is still in phase I trial for Dyslipidaemias in Australia (PO) (Lyndra pipeline, May 2024)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in Australia (PO, Capsule)